Oral nutraceutical antioxidants have shown disappointing clinical results in reducing oxidationinduced age-related cataract and other ocular diseases. Based on the hypothesis that nutraceuticals do not adequately reach the lens by oral administration, we have developed a unique topical antioxidant formulation whose active ingredients have the reported ability to reduce oxidative stress through free radical scavenging and chelating activity. This topical nutraceutical formulation was designed to mimic the in vivo activity of multifunctional antioxidants, compounds which are being developed in our laboratory to independently scavenge free radicals and selectively bind redox metals.
INTRODUCTION
The Free Radical Theory of Aging was proposed by Denham Harman in the 1950s. This theory postulates that oxygen free radicals which are formed endogenously from normal metabolic processes play a role in aging [2] . This hypothesis sparked research which has evolved into the field of redox biology where the relationship between reactive oxygen species (ROS) and biological function(s) and disease are being identified and defined. ROS are oxygen containing reactive chemical species that are produced intracellularly as natural byproducts of normal oxygen metabolism both from inside (endogenous) and outside (exogenous) sources. Endogenous ROS plays important roles in cell signaling and homeostasis, with superoxide, hydrogen peroxide, and nitric oxide species being the most prominent. Exogenous ROS is generated from outside sources that include xenobiotics (e.g. drugs, pesticides or carcinogens), environmental pollutants (e.g. carbon based smoke), and exposure to light and other forms of radiation. The presence of free transition metals such as iron, copper, or zinc can also contribute to ROS [3] . The levels of these metals increase with aging and the presence of select diseases, in addition to from exogenous sources including the use of tobacco [3] [4] [5] [6] [7] [8] . In the presence of superoxide and hydrogen peroxide radicals, transition metals such as iron or copper catalyze the generation of highly reactive hydroxyl radicals through the Fenton reaction [9] .
Oxidative Stress and the Eye ROS plays important roles in the regulation of cell survival. Moderate levels function as signals which promote cell proliferation and survival, while increased levels can induce cell death [10] . ROS production by mammalian mitochondria is especially important because it underlies oxidative damage in many pathologies and contributes to retrograde redox signaling from the organelle to the cytosol and nucleus [11] . ROS is regulated by a number of endogenous antioxidant and enzyme systems [12] [13] [14] . The breakdown of these protective antioxidant systems with age or disease results in an elevated generation of ROS, with this imbalance being defined as oxidative stress. The Fenton product induced oxidative stress; however, it cannot be readily reduced because no endogenous detoxification systems neutralize the toxic hydroxyl radicals [15] . ROS damages lipids, proteins, and DNA. Moreover, ROS has been detected in cancers and age related diseases linked to neurodegeneration, inflammation, diabetes, and vision and sensory loss. Our studies have focused on reducing ocular oxidative stress because the eye is a unique organ which is exposed to both endogenous and exogenous ROS. In the eye, endogenous ROS is associated with the high neural retinal metabolism required to convert light to electrical signals that are sent to the brain, while the exogenous ROS comes from light interacting with oxygen, both on the outer surface of the eye and from passing through the eye to the retina. This increase in endogenous and exogenous ocular ROS is also accompanied by the accumulation of select transition metals; for example, iron with age or environmental exposure to smoke, especially from tobacco [7, 16, 17] .
Clinical Challenges with Antioxidant Therapy
The link between oxidative stress and age-related diseases has sparked programs designed to encourage one to acquire a healthy lifestyle which includes a diet rich in antioxidants. This has also spawned a nutraceutical industry which provides the consumer with numerous natural antioxidant supplements. However, the scientific evaluation of dietary changes and antioxidant supplements have been limited, while clinical evaluations have been largely inconclusive or disappointing [18] [19] [20] . This is especially true for clinical studies on the prevention of cataracts where oxidative stress has been established to play a key role in the development of age-related cataracts [21] [22] [23] . As the largest avascular tissue in the body, the lens is composed of an anterior monolayer of cuboidal lens epithelial cells (LECs) and specifically aligned fiber cells which are all enclosed in a collagenous capsule. Because it is avascular, it only receives nutrients from the aqueous humor in the anterior chamber. LECs contain mitochondria and other organelles, large amounts of cytoskeletal proteins including microtubules and actin, in addition to structural proteins called crystallins. These divide at the germinative zone and move to the equator, where they elongate and differentiate into lens fibers to form highly ordered concentric shells. Mitochondria and nuclei in these fibers cells are lost, while new crystallin proteins are produced. Differentiation occurs throughout life. Accordingly, the age of fiber cells increases with their location toward the center. At the lens nucleus, the fiber cells correspond to the fetal stage. Structurally, lens fiber cells and their proteins are highly ordered; this order must be maintained for lens clarity. The unique structural and biochemical differences between the epithelial and fiber cells result in significant differences in redox biology. These differences make the lens highly susceptible to oxidative stress, which can cause irreversible protein and membrane changes that eventually result in loss of transparency, i.e., cataract formation.
Despite the established link between oxidative stress and cataract formation, randomized, double-masked, placebo-controlled clinical trials with populations ranging from 1,000 to nearly 40,000 participants have failed to show efficacy when antioxidants or vitamin formulations were orally administered [23, 24] . Since the avascular lens receives all of its nutrients from the aqueous humor, this failure may be due to the inability of oral antioxidants to adequately cross the bloodaqueous barrier to achieve therapeutic levels in the lens. Alternatively, the antioxidant activity may not be potent enough. These possibilities are supported by results from the AREDS trials where retinal but no lens efficacy was observed [24] [25] [26] . However, retinal efficacy by the AREDS formulations is very limited.
Development of Multifunctional Antioxidants.
We have developed a new class of synthetic antioxidants called multifunctional antioxidants (MFAOs) [27] [28] . These compounds use innovative therapeutic strategy, which involves multifunctional metal attenuating antioxidants targeting multiple mechanisms of radical action that are superior to compounds which only bind transition metals or scavenge free radicals. They not only scavenge free radicals but also independently sequester and redistribute free transition metals that can participate in the Fenton generation of toxic hydroxyl radicals (Figure 1 ). MFAOs contain a 2-amino-5-hydroxy-pyrimidine group that has 100-fold greater scavenging activity than vitamin E. They are orally active and achieve therapeutic levels in the lens in addition to the retina. In rats, MFAOs reduce cataract formation induced by whole-head gamma irradiation, as well as diabetic ER stress and UV light [1, 29] . They also protect both the neural retina and photoreceptor layer against retinal degeneration induced by light in dark-adapted rats [30] , in addition to reducing amyloid beta plaque formation in the brain of Alzheimer's transgenic mice [27] . Recent studies also suggest that these compounds protect rats from noise-induced neurodegenerative damage [31] .
Topical Nutraceutical Antioxidant Formulation for Eye Health
Since the clinical development of these agents will take years to achieve stringent FDA approval, we have investigated whether the biological activity of MFAOs in the eye can, at least in part, be mimicked by a combination of unique nutraceuticals. Based on their observed ocular antioxidant effects, we have developed and patented a nutraceutical formulation [32] (referred to here as topical nutraceutical) containing astaxanthin, resveratrol, (-)-epigallocatechin gallate (EGCG), and ethyl pyruvate (Figure 2 ). These were chosen for their following biological importance:
Astaxanthin is a carotenoid with 10-fold higher antioxidant activity than zeaxanthin, lutein, canthaxantin, and β-carotene. It is called "super vitamin E" because it has 100-fold higher antioxidant activity than α-tocopherol (vitamin E) [33] . In polar solvent, astaxanthin exists in equilibrium with its keto-enol form which possesses a hydrogen atom capable of breaking the free radical reaction in a manner similar to that of α-tocopherol.
Resveratrol is an antioxidant present in red wine [34] that has been touted for its anti-aging properties [35, 36] . Its antioxidant activity results from the presence of conjugated hydroxyl 
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groups. Oral administration of resveratrol has limited bioavailability because of its rapid metabolism by glucuronide and sulfate conjugation in the intestine and liver [37] .
Topical application increases its bioavailability by bypassing this rapid, first pass metabolism. Long-term administration of resveratrol to mice has been reported to slow age-related degeneration and functional decline, including cataract formation [38] . In mice that are injected with LPS to induce endotoxin-induced uveitis (EIU) undergo treatment with resveratrol prior to LPS injection reduced inflammation through inhibition of oxidative damage and redox-sensitive NF-κB activation [39] . It is also believed to ameliorate oxidative stress associated with AMD and glaucoma [40] . The addition of 50 and 100 mmol/L of resveratrol reduced the in vitro proliferation of human RPE19 cells by 10% and 25% respectively, and protected the RPE cells from hydrogen peroxide-induced cell death [41, 41] .
EGCG, the most abundant component in green tea, has 10-fold greater antioxidant activity than vitamin E. It also has the reported ability to chelate redox reactive iron and copper [43] [44] [45] [46] . When topically applied to the eye, it reaches the lens [47] . Studies with cultured human LECs have shown that EGCG reduces ROS associated with UVB radiation and hydrogen peroxide [46, [48] [49] [50] . It also protects human RPE cells against UVA-induced damage [51] and retina photoreceptors against oxidation induced by sodium nitroprusside [52] .
Pyruvate is an endogenous antioxidant that can scavenge radicals [53] [54] [55] . When administered as the ethyl ester prodrug, it has anti-inflammatory activity and reduces organ system damage in ischemia/reperfusion injury and hemorrhagic and endotoxic shock [56] . It also beneficially effects cytokine expression and proinflammatory gene regulation [57] . When topically applied, both sodium pyruvate and its ethyl ester penetrate the cornea [58, 59] . Both in vitro lens and in vivo diabetic rat studies report that pyruvate delayed sugar cataract formation by decreasing lens sorbitol levels [60] , lipid peroxidation [61] , and promoting the reduction of pyruvate to lactate [62] . The i.p. administration of pyruvate also reduces selenite cataract formation in rats [63, 64] . These four unique nutraceutical antioxidants possess the ability to reduce oxidative stress through both free radical scavenging and chelating activity designed to mimic the promising effects of MFAOs in the eye. Together, these nutraceuticals are topically delivered in a viscous proprietary carbomer vehicle with established topical adhesion properties which have been shown to enhance the ocular uptake of select drugs [65] . The topical delivery of these nutraceuticals was chosen based on the hypothesis that oral administration of antioxidants generally fails to achieve adequate levels in the anterior segment, including the lens, and because topical delivery bypasses first pass metabolism. Using rat models associated with cataract formation, light-induced retinal degeneration, and scopolamine-induced dry eye, the therapeutic potential of the topical administration of a 3% suspension of the nutraceutical components in this formulation have been compared to other agents. These animal studies were approved by the University of Nebraska Medical Center Institutional Animal Care and Use Committee and conformed to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. For the lens studies, the following were included: Ocu-GLO TM purchased from Animal Health Quest, Bellingham, WA. The capsular contents of this oral antioxidant, designed to reduce cataracts in dogs, were dissolved in Tween 80 so that administration by gavage of the Tween mixture delivered the manufacturer's suggested amount of nutraceutical formulation per weight of rat; Kinostat  , a topical aldose reductase inhibitor (ARI) from Therapeutic Vision, Inc., Omaha, NE that was administered b.i.d.; Imirestat (AL1576), an ARI from Alcon Pharmaceuticals, Ft. Worth, TX, that was orally administered in standard rat chow at a concentration of 0.0125 wt % to deliver aldose of ~17 mg/kg/day; JHX-4 (4-(5-hydroxypyrimidin-2-yl)-N,N-dimethyl-3,5-dioxopiperazine-1-sulfonamide, a MFAO that was synthesized as previously described 28 . Topical MFAO JHX-4, prepared by suspending 3% (w/w) of compound in Optixcare Eye Lube vehicle, was administered b.i.d; oral JHX-4 was administered as 0.05% (w/w) in standard rat chow to give a dose of ~49 mg/kg/day. The dry eye studies also utilized Optixcare Eye Lube + Hyaluron from Aventix Animal Health and I-drop Vet Plus which was purchased from imed Pharma, Dollard-desOrmeaux, QC, Canada. All three were delivered b.i.d. The retinal degeneration studies utilized the topical nutraceutical b.i.d compared to JHX-4 delivered orally in chow at a dose of ~49 mg/kg/day.
Cataracts
Worldwide, age-related cataracts are the leading cause of blindness in addition to being one of the most common causes of visual impairment in the United States [66] . Since the progression of agerelated cataracts is gradual, it has been estimated that a 10 year delay in cataract progression could reduce the need for cataract surgery by 50% [67] . However, the development of pharmaceutical treatments for age-related cataracts has been hampered by the lack of established animal models that develop age-related cataracts over practical time periods. Therefore, the only practical way of evaluating the efficacy of potential anti-cataract agents has been to focus on biomarkers associated with experimentally induced oxidative stress. Our studies have focused on reducing the lenticular effects of endogenous and exogenous generated oxidative stress.
Diabetic Cataracts
Diabetic cataracts develop rapidly within weeks in young rats after the induction of diabetes mellitus (DM). This development is also associated with the generation of endogenous ROS [1, 29] . Diabetic cataracts are commonly called "sugar" cataracts because the lens changes are not specific to DM but also occur with galactosemia [68] . It has been established in both diabetic and galactosemic rat lenses that the enzyme aldose reductase reduces excess glucose or galactose to the respective sugar alcohols (polyols) sorbitol or galactitol [68] . The intracellular accumulation of these polyols in lens epithelial cells (LECs) and fiber cells causes osmotic changes that alter membrane permeability and begin the cascade of biochemical changes that lead to cataract formation [69, 70] . The requirement for polyol-induced osmotic change has been confirmed by in vitro lens culture studies and in vivo animal studies [69, 71] . In LECs, polyol-linked osmotic stress also affects the endoplasmic reticulum (ER) and the osmotic induction of ER stress leads to the subsequent generation of endogenous ROS through an unfolded protein response (UPR) [72] [73] [74] . Sugar cataracts are inhibited in diabetic and galactosemic animals by ARIs which prevent lens polyol formation (and the subsequent induction of ER stress). However, sugar cataracts can only be delayed by antioxidants because they only address the generated endogenous ROS but not the polyol-induced osmotic stress. This was experimentally confirmed in the studies described below where the effects of antioxidants and ARIs were compared. For these studies, DM was induced in young (100 g) Sprague Dawley rats by tail vein injection of 75 mg/kg of streptozotocin [1] . Next, all rats with average blood glucose levels > 300 mg/dL were randomly divided into groups. were monitored weekly using a hand-held slit lamp following the dilation of each eye with 1% tropicamide ophthalmic solution. Lens changes were evaluated by portable slit lamp using a scale of 0-3 with 0 corresponding to no lens changes; 0.5 to suture accentuation; 1 to vacuole formation; 2 to cortical opacity; and 3 to mature cataract. As summarized in Figure 3 , slit lamp examinations indicated that cataract development in untreated diabetic rats rapidly progress to the cortical or mature stage within 7 weeks of the induction of DM. This cataract formation was inhibited by both topical administration of the ARI Kinostat  or oral ARI imirestat [65, 75] . In contrast, oral administration of the MFAO JHX-4 or the oral anti-cataract antioxidant/vitamin formulation Ocu-GLO TM only slightly delayed the progression of cataract, with lens changes ranging from cortical to mature cataracts present at the end of the study period. This delay in cataract formation was much greater in rats receiving the topical nutraceutical with primarily suture accentuation, the initial stage of sugar cataract development that occurs before the vacuole formation only present. These slit lamp observations were subsequently confirmed at study completion by microscopic examination of the dissected lenses, where no lens changes were evident in the ARI treated rats. Additionally, measurement of glycosylated hemoglobin levels (HbA1c, Bayer Metrika A1cNOW Plus System test kit, San Diego, CA) indicated that all groups were similarly hyperglycemic over the course of this study, thereby removing the possibility that these observed differences in sugar cataract formation were linked to differences in the severity of diabetes.
UV Induced Cataracts
Our eyes are constantly exposed to UV irradiation from sunlight and artificial lighting. Moreover, excess exposure to UV irradiation is a major risk factor for cataract and macular degeneration [76] . UV light damages the lens through the generation of exogenous ROS that decreases lens reduced glutathione (GSH) levels and leads to lens opacification. In young albino rats exposed to UV irradiation, this decrease in GSH levels occurs within 2-3 days of UV exposure [77, 78] . To investigate the efficacy of antioxidants in preventing this reduction of GSH levels, young albino rats were anesthetized and one eye was patched to serve as a dark control. The contralateral eye was then exposed to 1600 µw/cm 2 of UV light (280-360 nm, UVmax 306 nm) for 15 minutes which resulted in a significant decrease in lens GSH levels within 2 days after exposure. A similar the progression of sugar cataract formation. All agents were administered from the onset of diabetes. Oral JHX-4 and imirestat included in the graph were normalized against untreated diabetic rats from a separate study. 1 The control was not statistical different (p<0.05) from either oral JHX-4 or oral Ocu-Glo TM . The Topical Nutraceutical was significantly (p<0.05) different from both the control and topical Kinostat  or oral imirestat. Values represent mean ± SEM; n=5 rats.
significant decrease was also observed in Ocu-GLO TM rats where oral treatment was initiated 3 days prior to UV exposure. In contrast, similar exposure of rats treated with either 3% MFAO JHX-4 or topical nutraceutical b.i.d. beginning 3 days before UV exposure protected against a significant loss of lens GSH levels. (Figure 4A ).
To confirm that the reduction of GSH levels was linked to ROS generated oxidation in the lens, the lenticular levels of oxidized 4-hydroxynonenol (4-HNE) were also examined using an OxiSelect HNE Adduct Competitive ELISA Assay Kit (Cell Biolabs, Inc., San Diego, CA). As shown in Figure 4B , lens levels of 4-HNE increased with UV exposure and these levels were reduced by all antioxidant treatments. Compared to the 4-HNE levels in lenses from untreated rats exposed to UV irradiation, 4-HNE levels were only significantly reduced in rats treated with topical JHX-4 (p<0.01) and topical nutraceutical (p<0.05), while the 4-HNE levels in the oral Ocu-GLO TM treated rats were not significantly reduced. However, when comparing 4-HNE levels in the exposed and unexposed contralateral eyes, the 4-HNE lens levels were statistically similar only in the MFAO JHX-4 treated rats, indicating that the protective antioxidant effects of the MFAO is slightly better compared to the topical nutraceutical. In preliminary studies, a similar Figure 4 A. Reduction of lens GSH levels in young Sprague Dawley rats exposed to UV irradiation while their contralateral eye was covered and served as the non-exposed control. Compared to their covered contralateral eyes, significantly lower GSH levels were observed 2 days after UV exposure in lenses for untreated and oral antioxidant/vitamin formulation Ocu-GLO TM treated rats, while no significant decrease was observed in rats treated with either topical MFAO JHX-4 or topical nutraceutical. B. 4-Hydroxynonenol (4-HNE) levels in the rat lenses directly correlated with the decrease in lens GSH levels in A. Lens 4-HNE levels measured 2 days after exposure to UV irradiation were reduced by antioxidant treatments in the order: topical 3% JHX-4 > topical nutraceutical> oral Ocu-GLO TM >untreated. With the exception of topical JHX-4 treated rats, all rats had significantly higher (p < 0.01) levels of 4-HNE in the UV exposed lenses compared to the levels in the contralateral non-irradiated control lenses. Mean ± SEM; n = 5-6 rats. An asterisk (*) denotes a significant difference in A (p < 0.05) in B (p < 0.01) compared to untreated irradiated lenses; the hatched symbol (#) denotes a significant difference (p < 0.01) compared to irradiated Ocu-GLO TM treated lenses. beneficial protection was also observed when JHX-4 was orally administered 3-6 days prior to UV exposure.
Light-Induced Retinal Degeneration
When dark adapted rats are exposed to white light, ROS is generated in the neural retina along with iron dysregulation and the release of iron from ferritin [79, 80] . This has been proposed to be an experimental animal model for dry AMD [81] , and MFAOs have been shown by biochemistry, electrophysiology and histology to beneficially protect the neural retinas of these rats [30] . Since the topical nutraceutical was designed as a nutraceutical MFAO mimic, the topical nutraceutical was also evaluated in this animal model despite the fact that topically administered drugs are known, in general, to have only minimal effects on the retina. For these studies, Wistar rats were orally treated with either diet containing 0.05% of the MFAO JHX-4 or topically treated b.i.d. with topical nutraceutical from the onset of two-week dark adaption. Each rat was then individually exposed for 3 hours to 1000 lx of cool white fluorescent light (Lights of America, Los Angeles, CA). An additional group of non-treated rats were also placed into the light box apparatus for three hours, but not exposed to light (non-light-damaged rats, NLD). Immediately following light exposure, a portion of light exposed rats from each group and non-light exposed rats were immediately euthanized, the eyes enucleated, and the neural retinas carefully dissected and frozen on dry ice. The remaining rats in each group were then returned to the dark environment. Following 5-7 days of dark recovery from intense light exposure, the retinal neural functions of the remaining rats in each group along with their corresponding non-light-damaged controls were evaluated by non-invasive electroretinography (ERG) using a UTAS system (LKC Technologies Inc., Gaithersburg, MD) [30] . Finally, all rats were euthanized seven days after light exposure by carbon dioxide asphyxiation and the dorsal ventral orientation of each eye was marked with a cautery tool. The eyes were then enucleated and fixed in a 3:1 (v/v) methanol: acetic acid solution, before being processed for subsequent morphological analyses. Exposure to light resulted in an increase of oxidative stress markers that include 4-HNE adducts formed with histidine following the non-enzymatic oxidation of polyunsaturated fatty acids and nitrotyrosine-modified proteins resulting from tyrosine residues being oxidized by peroxynitrite formed by the reaction of nitric oxide with superoxide anions. As shown in Figure 5 , both the 4-hydroxynonenal (HNE)-histidine adduct levels (A) and nitrotyrosine adduct levels (B) determined by ELISA (Cell Biolabs, Inc., San Diego, CA), increased in the neural retinas of untreated rats exposed to light after 2-weeks of dark adaptation. Neither oxidative marker significantly increased in similar light exposed rats treated with the MFAO JHX-4 ( Figure 5 A, B) . Significantly less increases were also observed in the topical nutraceutical treated rats. ROS and free radicals generated by retinal exposure to acute excessive light were also mediated by the thioredoxin (TRx) / thioredoxin reductase (TRxR) defense system [82] . Therefore, the expression levels of both TRx and TRxR in the neural retinas of rats were examined by western blot using commercially available antibodies against TRx (Cell Signaling Technology, Danvers, MA) and TRxR (Abcam, Inc., Cambridge, MA). The expression of both increased in untreated rats exposed to light ( Figure 5C , D) and treatment with either JHX-4 or topical nutraceutical significantly lowered the expression of TRxR in the light exposed neural retinas. However, only the MFAO JHX-4 reduced the expression of TRx.
Histological measurements confirmed the reduction of retinal oxidative stress. Intense light exposure results in photoreceptors thinning in the outer nuclear layer (ONL), with damage more pronounced in the superior compared to inferior hemisphere ( Figure 6A, B) . The photoreceptor layer in light exposed rats treated with JHX-4 showed decreases of 4% in the inferior hemisphere and 21% in the superior hemisphere ( Figure 6C ). Only a slight decrease in both the inferior hemisphere and superior hemisphere showed when compared to dark adapted rats that were not exposed to light. In contrast, the photoreceptor layer was only slightly protected in the Optixcare EH TM treated rats ( Figure 6D ). This difference in photoreceptor thickness protection was more apparent by ERG measurements, a procedure that measures the function of photoreceptors (rods and cones), inner retinal cells (bipolar and amacrine cells), and ganglion cells through the measurement of electrical responses [83] [84] [85] . The a-wave is derived from the rods and cones of the outer photoreceptor layers while the b-wave is derived from the inner retina, predominantly Muller and ON-bipolar cells. This b-wave is the most common component of the ERG used in clinical and experimental analysis of retinal function. Photopic measurements are generally a cone response while rod function is Both the adduct and expression levels were increased in light exposed untreated rats and reduced by antioxidant treatments. Mean ± S.D.; n=6. An asterisk (*) denotes a significant difference (p<0.05) when compared to the untreated, non-light-damaged group while the hatched symbol (#) denotes a significant difference (p<0.05) compared to the untreated light damaged group. present in the scotopic measurements. In the untreated light exposed rats, the average maximal scotopic a-wave and b-wave amplitudes were significantly (p<0.05) reduced by 30% and 25% respectively, with the maximum amplitude being significantly reduced by 25% in the photopic ERG b-wave response. None of these reductions were observed in similar light exposed rats treated with the MFAO JHX-4. In contrast, no ERG protection was observed with the topical nutraceutical.
Figure 6
Light-induced destruction of the retinal outer nuclear layer (ONL) can be reduced by the presence of antioxidants. Photomicrographs of the superior hemisphere illustrate photoreceptor thinning in ONL (arrow). The NL thickness of non-light damaged and light damaged retinas treated with or without the multifunctional MFAO JHX-4 or the topical nutraceutical are below their respective photomicrograph. The MFAO had superior protection. n=3. Mean ± S.E.M.
Keratoconjunctivitis Sicca (KCS)
Keratoconjunctivitis sicca (KCS), commonly called dry eye, occurs in nearly five million Americans 50 years of age and older [86] . Although more frequently experienced in the elderly, KCS can occur at any age with symptoms that include dryness/itching, burning/stinging, watering or a gritty or sandy sensation. It can also include a sensitivity to light, blurry vision, or difficulty with night vision. These symptoms can be temporary or can increase to become chronic. KCS results from either lacrimal glands that fail to produce enough of the watery component of tears to maintain a healthy eye surface, or inflammation due to the meibomian gland function, which makes the lipid or oily part of tears that slows tear evaporation and keeps the tears stable. The first line of therapy for KCS is the use of "comfort agents" that include non-prescription (OTC) artificial tears, gels, gel inserts, and ointments.
They offer temporary relief and provide an important replacement of naturally produced tears in patients with aqueous tear deficiency. Subsequently, as KCS is also linked to oxidative stress and inflammation, prescription anti-inflammatory, or immunosuppressant medications including cyclosporin or temporary corticosteroids may be used to decrease corneal damage, increase basic tear production, and reduce the symptoms of dry eye. Nutraceuticals including combined antioxidants and omega-3 essential fatty acid formulations [87] or topical epigallocatechin gallate [88] and castor oil have also been used.
Optixcare
TM carbomer gel and carbomer gel containing hyaluronic acid formulations are comfort agents used in the veterinary market for alleviating the clinical symptoms of dry eye. Since the ingredients in our topical nutraceutical formulation have been reported to demonstrate not only antioxidant but also anti-inflammatory activity, studies comparing the effects of the topical nutraceutical to carbomer comfort agents were compared. In these studies, KCS was induced in adult female Lewis rats by twice-daily subcutaneous injection of a 0.1 mL aqueous solution containing 24 mg of scopolamine (48 mg total dosage per day) [89] . The tear flow in these rats was measured weekly prior using Zone-Quick™ Phenol Red Threads (FCI Ophthalmics, 
CONCLUSION
The results demonstrate that the topical application of an antioxidant formulation with combined free radical scavenging, transition metal binding, and anti-inflammatory activity has beneficial effects on reducing oxidative stress that is associated with age-related ocular changes. Moreover, the application this topical nutraceutical mimics to some extent the effects of MFAOs in the eye. The small beneficial effects of the topical nutraceutical on oxidation-linked retinal changes were unexpected, as agents topically applied to the eye generally do not reach the retina. Retinal antioxidant efficacy is anticipated to increase by using a combination of oral and topical administration of the formula ingredients. For the veterinary market, this formulation has been licensed to CLC MEDICA, Waterdown, ON, Canada and is being marketed as Optixcare TM Eye Health primarily to veterinary ophthalmologists. Clinical observations to date suggest that this formulation is beneficial, not only for treating KCS but also apparently delaying age-related cataracts. During its use, an interesting new clinical indication for Optixcare TM Eye Health has come from observations by several veterinary ophthalmologists. This indication is that this topical nutraceutical with antioxidant/antiinflammatory/chelation properties reduces tear staining (epiphora) in dogs. Tear staining are reddish-brown streaks under a dog's (or cat's) eyes present in the medial canthus that are usually caused by epiphora, i.e., an overflow of tears. The color comes from porphyrins, which are naturally occurring molecules containing iron that are formed as waste products from the breakdown of red blood cells and exposure to sunlight that can darken these stains. This condition is much more prevalent in certain breeds (for example, the toy poodle, Maltese, the Lhasa Apso, and the Shih Tzu), and is much more obvious in animals with light-colored coats. While tear Figure 7 Effect of topical carbomer gels on tear flow in scopolamine injected rats. Continuous scopolamine injections resulted in decreased tear flow in both the untreated control rats and rats treated with the comfort agents Optixcare TM , Optixcare TM with hyaluronic acid (HA), and i-Drop hyaluronic acid (HA). Tear flow was maintained in similar rats treated with the topical nutraceutical. SEM; n = 6 rats. staining is generally no more than a minor annoyance, it can also be a symptom of serious eye health problems that include ingrown eyelashes, infections, unusually large tear glands, usually small tear duct openings, entropion, glaucoma, ear infections, or brachycephalic syndrome. Tear staining from excess tearing can also result from certain medications, exposure to secondhand smoke, stress, and diets. At present, a multi-centered clinical trial with Optixcare TM Eye Health is being conducted to validate this new clinical indication.
The ability to prevent KSC is also in the process of being clinically investigated in humans with studies anticipated to begin in 2016. While a topical formulation of select antioxidant with antioxidant/anti-inflammatory/chelation properties appears to be promising for reducing agerelated oxidative stress, it is anticipated that future beneficial effects will become apparent through extended clinical use as an OTC medication and established through anticipated future clinical trials.
